Scotia Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.17M | Sell |
4,861
-304
| -6% | -$142K | 0.01% | 444 |
|
|
2025
Q4 | $2.34M | Sell |
5,165
-756
| -13% | -$326K | 0.01% | 424 |
|
|
2025
Q3 | $2.32M | Sell |
5,921
-563
| -9% | -$235K | 0.01% | 422 |
|
|
2025
Q2 | $2.89M | Buy |
6,484
+412
| +7% | +$190K | 0.01% | 368 |
|
|
2025
Q1 | $2.94M | Sell |
6,072
-695
| -10% | -$324K | 0.02% | 349 |
|
|
2024
Q4 | $2.73M | Sell |
6,767
-573
| -8% | -$266K | 0.01% | 358 |
|
|
2024
Q3 | $3.41M | Sell |
7,340
-458
| -6% | -$220K | 0.02% | 331 |
|
|
2024
Q2 | $3.65M | Buy |
7,798
+297
| +4% | +$129K | 0.02% | 301 |
|
|
2024
Q1 | $3.14M | Buy |
7,501
+222
| +3% | +$93.8K | 0.02% | 318 |
|
|
2023
Q4 | $2.96M | Sell |
7,279
-638
| -8% | -$236K | 0.02% | 303 |
|
|
2023
Q3 | $2.75M | Sell |
7,917
-617
| -7% | -$216K | 0.02% | 302 |
|
|
2023
Q2 | $3M | Buy |
8,534
+371
| +5% | +$125K | 0.02% | 290 |
|
|
2023
Q1 | $2.57M | Sell |
8,163
-71
| -0.9% | -$21.3K | 0.02% | 312 |
|
|
2022
Q4 | $2.38M | Buy |
8,234
+135
| +2% | +$41.1K | 0.02% | 325 |
|
|
2022
Q3 | $2.35M | Sell |
8,099
-7,788
| -49% | -$2.24M | 0.02% | 321 |
|
|
2022
Q2 | $4.48M | Sell |
15,887
-4,099
| -21% | -$1.1M | 0.03% | 233 |
|
|
2022
Q1 | $5.22M | Sell |
19,986
-3,497
| -15% | -$830K | 0.03% | 249 |
|
|
2021
Q4 | $5.16M | Buy |
23,483
+7,458
| +47% | +$1.45M | 0.03% | 252 |
|
|
2021
Q3 | $2.91M | Sell |
16,025
-16,189
| -50% | -$3.16M | 0.02% | 335 |
|
|
2021
Q2 | $6.5M | Buy |
32,214
+180
| +0.6% | +$37.7K | 0.05% | 214 |
|
|
2021
Q1 | $6.88M | Buy |
32,034
+14,750
| +85% | +$3.24M | 0.06% | 193 |
|
|
2020
Q4 | $4.08M | Buy |
17,284
+4,055
| +31% | +$930K | 0.04% | 238 |
|
|
2020
Q3 | $3.6M | Sell |
13,229
-2,141
| -14% | -$591K | 0.04% | 224 |
|
|
2020
Q2 | $4.52M | Sell |
15,370
-521
| -3% | -$141K | 0.06% | 165 |
|
|
2020
Q1 | $3.78M | Sell |
15,891
-1,201
| -7% | -$275K | 0.05% | 178 |
|
|
2019
Q4 | $3.75M | Buy |
17,092
+120
| +0.7% | +$24.3K | 0.04% | 212 |
|
|
2019
Q3 | $2.88M | Sell |
16,972
-769
| -4% | -$136K | 0.03% | 238 |
|
|
2019
Q2 | $3.25M | Buy |
17,741
+590
| +3% | +$103K | 0.04% | 219 |
|
|
2019
Q1 | $3.15M | Sell |
17,151
-75
| -0.4% | -$13.9K | 0.04% | 218 |
|
|
2018
Q4 | $2.85M | Buy |
17,226
+438
| +3% | +$75.9K | 0.04% | 223 |
|
|
2018
Q3 | $3.24M | Sell |
16,788
-1,203
| -7% | -$214K | 0.04% | 226 |
|
|
2018
Q2 | $2.91M | Hold |
17,991
| – | – | 0.04% | 230 |
|
|
2018
Q1 | $2.93M | Buy |
17,991
+575
| +3% | +$93.9K | 0.04% | 236 |
|
|
2017
Q4 | $2.61M | Buy |
17,416
+615
| +4% | +$91.1K | 0.03% | 257 |
|
|
2017
Q3 | $2.55M | Sell |
16,801
-169
| -1% | -$25.4K | 0.04% | 251 |
|
|
2017
Q2 | $2.19M | Sell |
16,970
-1,795
| -10% | -$216K | 0.04% | 239 |
|
|
2017
Q1 | $2.06M | Sell |
18,765
-542
| -3% | -$47.7K | 0.04% | 255 |
|
|
2016
Q4 | $1.42M | Sell |
19,307
-3,814
| -16% | -$310K | 0.02% | 357 |
|
|
2016
Q3 | $2.02M | Buy |
23,121
+13,290
| +135% | +$1.26M | 0.04% | 300 |
|
|
2016
Q2 | $848K | Buy |
9,831
+290
| +3% | +$25.1K | 0.02% | 417 |
|
|
2016
Q1 | $759K | Buy |
9,541
+6,766
| +244% | +$612K | 0.02% | 401 |
|
|
2015
Q4 | $349K | Hold |
2,775
| – | – | 0.01% | 648 |
|
|
2015
Q3 | $290K | Buy |
2,775
+170
| +7% | +$21.8K | 0.01% | 655 |
|
|
2015
Q2 | $315K | Buy |
+2,605
| New | +$328K | 0.01% | 616 |
|
|
2014
Q1 | – | Sell |
-246,179
| Closed | -$18.3M | – | 612 |
|
|
2013
Q4 | $18.3M | Sell |
246,179
-32,250
| -12% | -$2.25M | 0.44% | 44 |
|
|
2013
Q3 | $21.1M | Buy |
278,429
+32,950
| +13% | +$2.62M | 0.57% | 40 |
|
|
2013
Q2 | $19.6M | Buy |
+245,479
| New | +$18.1M | 0.76% | 28 |
|
Other funds holding VRTX
VCM
VPM
Scotia Capital's VRTX Position: Q1 2026 in Review
Scotia Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q1 2026, selling an estimated $142K and leaving 4,861 shares worth $2.17M. The position accounts for 0.01% of the portfolio, ranked #444.
Scotia Capital first reported a position in VRTX in Q2 2013 and has held it in 47 quarters since. The position peaked at $21.1M in Q3 2013. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Scotia Capital held 4,861 shares of Vertex Pharmaceuticals worth $2.17M as of Q1 2026.
- Scotia Capital sold 304 Vertex Pharmaceuticals shares in Q1 2026, an estimated $142K.
- Vertex Pharmaceuticals made up 0.01% of Scotia Capital's portfolio in Q1 2026, its #444 holding.
- Scotia Capital first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Scotia Capital's Vertex Pharmaceuticals position peaked at $21.1M in Q3 2013.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.